Acadia Pharmaceuticals Inc.

The sponsor maintains a concentrated focus on addressing complex neuropsychiatric conditions associated with neurodegenerative diseases. Research efforts center on therapeutic interventions for Parkinson's disease psychosis, a debilitating complication affecting patients with progressive motor disorders. The organization investigates treatment approaches for hallucinations and delusions that emerge in patients with established Parkinson's disease, seeking to improve both psychiatric symptoms and overall quality of life.

• Parkinson's Disease Psychosis
• Hallucinations and Delusions
• Movement Disorder Complications

The therapeutic strategy emphasizes managing the psychiatric manifestations that frequently accompany motor symptoms in neurodegenerative conditions, representing a specialized area of expertise in addressing the intersection between movement disorders and psychiatric symptomatology.